Roche faces UK pricing row over multiple sclerosis drug Ocrevus

Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

from Reuters: Business News https://ift.tt/2CDx2m3